Open this publication in new window or tab >>National Heart Centre Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.
National Heart Centre Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore, Singapore; School of Allied Health, University of Western Australia, Australia.
Department of Cardiology, MacKay Memorial Hospital, Taipei, Taiwan.
National Heart Centre Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore, Singapore.
Department of Cardiology, Hero Dayanand Medical College Heart Institute, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
National Heart Centre Singapore, Singapore; Department of Dermatology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands.
National Heart Centre Singapore, Singapore.
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre, University of Leicester, Leicester, United Kingdom.
Diabetes Research Centre, Leicester, United Kingdom; Department of Health Sciences, University of Leicester, Leicestershire, United Kingdom.
Department of Health Sciences, University of Leicester, Leicestershire, United Kingdom.
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Cardiovascular Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Care Institute of Medical Sciences, Ahmedabad, India.
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre, University of Leicester, Leicester, United Kingdom.
Leicester Real World Evidence Unit, Leicester, United Kingdom; NIHR Applied Research Collaboration-East Midlands, University of Leicester, Leicester, United Kingdom; Diabetes Research Centre, Leicester, United Kingdom.
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Nursing Sciences and Reproductive Health. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart Center, Department of Cardiology in Linköping.
National Heart Centre Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore, Singapore; George Institute for Global Health, Sydney, Australia; Department of Cardiology, University of Groningen, Groningen, the Netherlands.
Show others...
2023 (English)In: JACC. Asia, ISSN 2772-3747, Vol. 3, no 3, p. 349-362Article in journal (Refereed) Published
Abstract [en]
Background: In heart failure (HF), symptoms and health-related quality of life (HRQoL) are known to vary among different HF subgroups, but evidence on the association between changing HRQoL and outcomes has not been evaluated.
Objectives: The authors sought to investigate the relationship between changing symptoms, signs, and HRQoL and outcomes by sex, ethnicity, and socioeconomic status (SES).
Methods: Using the ASIAN-HF (Asian Sudden Cardiac Death in Heart Failure) Registry, we investigated associations between the 6-month change in a "global" symptoms and signs score (GSSS), Kansas City Cardiomyopathy Questionnaire overall score (KCCQ-OS), and visual analogue scale (VAS) and 1-year mortality or HF hospitalization.
Results: In 6,549 patients (mean age: 62 ± 13 years], 29% female, 27% HF with preserved ejection fraction), women and those in low SES groups had higher symptom burden but lower signs and similar KCCQ-OS to their respective counterparts. Malay patients had the highest GSSS (3.9) and lowest KCCQ-OS (58.5), and Thai/Filipino/others (2.6) and Chinese patients (2.7) had the lowest GSSS scores and the highest KCCQ-OS (73.1 and 74.6, respectively). Compared to no change, worsening of GSSS (>1-point increase), KCCQ-OS (≥10-point decrease) and VAS (>1-point decrease) were associated with higher risk of HF admission/death (adjusted HR: 2.95 [95% CI: 2.14-4.06], 1.93 [95% CI: 1.26-2.94], and 2.30 [95% CI: 1.51-3.52], respectively). Conversely, the same degrees of improvement in GSSS, KCCQ-OS, and VAS were associated with reduced rates (HR: 0.35 [95% CI: 0.25-0.49], 0.25 [95% CI: 0.16-0.40], and 0.64 [95% CI: 0.40-1.00], respectively). Results were consistent across all sex, ethnicity, and SES groups (interaction P > 0.05).
Conclusions: Serial measures of patient-reported symptoms and HRQoL are significant and consistent predictors of outcomes among different groups with HF and provide the potential for a patient-centered and pragmatic approach to risk stratification.
Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
health; heart failure; hospitalization; mortality; signs; symptoms
National Category
Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:liu:diva-202818 (URN)10.1016/j.jacasi.2023.03.015 (DOI)37323861 (PubMedID)2-s2.0-85160345778 (Scopus ID)
2024-04-222024-04-222025-02-20